About Cajal Neuroscience
Cajal Neuroscience is a Healthcare company based in Seattle (United States) founded in 2020 by Ian Peikon and Andrew Dervan. Neurodegenerative disease drugs are developed through genetic screening and multi-omics. Cajal Neuroscience has raised $96 million across 1 funding round from investors including Evotec, ARE and Bristol-Myers Squibb. Cajal Neuroscience offers products and services including Drug Discovery Platform and Therapeutics Development Services. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Cajal Neuroscience Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Cajal Neuroscience was founded in 2020 in Seattle, United States, within the biotechnology sector focused on neurodegenerative diseases. Viral tools and platforms are developed to screen targets with functional impacts on disease progression. Functional genetic screening and multi-omics approaches are utilized to advance precision medicine solutions for these conditions. Operations emphasize target identification and drug development based on genetic insights.
- Headquarters Seattle, United States
- Founders Ian Peikon, Andrew Dervan
- SectorsHealthcare
- Email••••••••
- Website cajalneuro.com
- Social LinkedIn X
- Legal Name Cajal Neuroscience Inc.
- Total Equity Funding$96M (USD)
in 1 rounds
- Latest Funding Round$96M (USD), Series A
Nov 2022
- InvestorsEvotec
& 6 more
Products & Services of Cajal Neuroscience
Cajal Neuroscience offers a comprehensive portfolio of products and services, including Drug Discovery Platform and Therapeutics Development Services.
Platform for identifying drug targets in neurodegenerative diseases using advanced analyses
Services to develop potential treatments for neurodegenerative conditions
Funding Insights of Cajal Neuroscience
Cajal Neuroscience has successfully raised a total of $96M through 1 strategic funding round. The most recent funding activity was a Series A round of $96 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $96M
- Total Rounds 1
- Last Round Series A — $96M
- First Round $96M
(Nov 2022)
- Investors Count 7
All 1 funding rounds of Cajal Neuroscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $96M | Series A | – | Lux Capital, TCG |
7 investors in total: 7 institutional.
Investors in Cajal Neuroscience
Cajal Neuroscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, ARE and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors | dolbyventures.com | San Francisco, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Drug discovery and development services are provided to biopharma sector. | 1993 | evotec.com | Hamburg, Germany | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for Cajal Neuroscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cajal Neuroscience
37 people are tracked at Cajal Neuroscience (8 in leadership, 13 in board & advisors, 16 in team).
| Name | Role | Group |
|---|---|---|
Ian Peikon | Co-Founder | Leadership |
Andrew Dervan | Co-Founder | Leadership |
Ben Logsdon | VP, Computational Biology | Leadership |
Valerie Huang | Vice President, Strategy and Corporate Development | Leadership |
Robert Hershberg | Co-founder, Executive Chairman Of The Board | Leadership |
Mindy Stoffels | Head of Human Resources | Leadership |
Alex Vaughan | Scientific Co-Founder | Leadership |
Jennifer Whitesell | Director - Translational Models And Biomarkers | Leadership |
Niranjan Bose | Advisor | Board & advisors |
Susan Hockfield | Board Member | Board & advisors |
Rob Hershberg | Co-Founder & Executive Chairman | Board & advisors |
Josh Wolfe | Board Member | Board & advisors |
Tim Kutzkey | Board Member | Board & advisors |
Martin Kampmann | Board Member | Board & advisors |
Anthony Zador | Board Member | Board & advisors |
Huda Zoghbi | Board Member | Board & advisors |
Charles Zuker | Board Member | Board & advisors |
Richard Hargreaves | Board Member | Board & advisors |
Jay Shendure | Board Member | Board & advisors |
David Holtzman | Board Member | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for Cajal Neuroscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cajal Neuroscience
2 dated milestones of Cajal Neuroscience across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Cajal Neuroscience is founded.
- Funding First funding round of $96.0M.
Competitors of Cajal Neuroscience
Cajal Neuroscience has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Cajal Neuroscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Cajal Neuroscience (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cajal Neuroscience
Complete news archive for Cajal Neuroscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cajal Neuroscience
Cajal Neuroscience was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Cajal Neuroscience is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Cajal Neuroscience is a funded company, having raised a total of $96M across 1 funding round to date. The company's 1st funding round was a Series A of $96M, raised on Nov 2022.
Cajal Neuroscience was founded in 2020 in Seattle, United States, within the biotechnology sector focused on neurodegenerative diseases. Viral tools and platforms are developed to screen targets with functional impacts on disease progression. Functional genetic screening and multi-omics approaches are utilized to advance precision medicine solutions for these conditions. Operations emphasize target identification and drug development based on genetic insights.
Cajal Neuroscience's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Cajal Neuroscience offers Drug Discovery Platform and Therapeutics Development Services.
Cajal Neuroscience has 7 investors. Key investors include Evotec, ARE, Bristol-Myers Squibb, The Column Group, and Lux Capital.
Cajal Neuroscience operates through Cajal Neuroscience Inc..